Alnylam develops RNA interference medicines that silence disease-related genes. Its marketed therapies address transthyretin amyloidosis and certain rare genetic disorders, with delivery technologies designed to suppress specific proteins. The company invests in expanding RNAi into larger indications, while generating revenue from its proprietary medicines and selected collaboration arrangements.
Alnylam Pharmaceuticals Inc. (ALNY) has a MarketKingdoms composite score of 61.4 (B-), an B-range rating. It ranks 1169th of 1,866 covered companies, 57th of 78 in Healthcare (sector average 64.4) and 7th of 12 in Biotechnology. Scores as of 2026-10-26.
Its strongest lenses are Expansion (growth) at 97 (Healthcare average 50) and Stock selection at 79 (Healthcare average 79). Its weakest lenses are Trend (momentum) at 3 (sector average 50) and Price (valuation) at 40 (sector average 50).
| Lens | Type | ALNY | Healthcare average | Biotechnology average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 79 | 79 | 78 | 44th |
| KPI momentum | Research signal | 77 | 78 | 75 | 43rd |
| Catalyst watch | Research signal | 67 | 74 | 74 | 10th |
| Price (valuation) | Fundamental lens | 40 | 50 | 30 | 35th |
| Expansion (growth) | Fundamental lens | 97 | 50 | 64 | 99th |
| Quality (profitability) | Fundamental lens | 74 | 50 | 55 | 85th |
| Trend (momentum) | Fundamental lens | 3 | 50 | 48 | 3rd |
The most recent call analysed was held on 2026-07-30 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -18.1%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 2.20, sector beta 1.58, industry beta -0.06; the factor model explains 34% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 74.9 | B+ | -17.8% |
| BeOne Medicines Ltd ADR (ONC) | 73.4 | B+ | -26.6% |
| Regeneron Pharmaceuticals Inc. (REGN) | 72.7 | B+ | +7.7% |
| Vertex Pharmaceuticals Incorporated (VRTX) | 68.1 | B | -7.5% |
| argenx SE ADR (ARGX) | 68.0 | B | -27.3% |
| Incyte Corporation (INCY) | 68.0 | B | -18.8% |
| Bio-Techne Corporation (TECH) | 60.4 | B- | -22.2% |
| Insmed Inc. (INSM) | 60.0 | B- | -48.5% |
Alnylam Pharmaceuticals Inc. financial statements · Healthcare sector ranking · Biotechnology industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.